Document Detail


FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa.
MedLine Citation:
PMID:  10522875     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the visible and quantitative anatomic distribution of fluorine-18-labeled L-DOPA in the healthy human brain, to thereby expand the understanding of extrastriatal sites of levodopa function, and to provide a broader foundation for clinical and research studies of fluoroDOPA accumulation in patients. METHODS: The authors performed dynamic three-dimensional fluoroDOPA PET imaging in 10 healthy volunteers and analyzed the images visually and quantitatively. Twenty-eight regions of interest were applied to parametric images of the uptake rate constant (using the multiple-time graphic plot method with cortical input function) and also were used to quantitate regional radioactivity at 80 to 90 minutes. The authors correlated the uptake constants with published human regional neurotransmitter and decarboxylation data. RESULTS: PET imaging with fluoroDOPA demonstrates trapping of labeled dopamine or its metabolites in substantial quantities in many areas of the brain other than the mesostriatal pathways, including considerable uptake in the serotonergic and noradrenergic areas of the hypothalamus and brainstem as well as in extrastriatal cerebral sites. Total fluoroDOPA uptake correlates best with the sum of catecholamine and indolamine concentrations in the brain and moderately well with regional activity of aromatic L-amino acid decarboxylase, but correlates poorly with extrastriatal dopamine concentration. CONCLUSION: Neither L-DOPA nor its radiolabeled analog fluoroDOPA is metabolized or accumulates specifically in dopaminergic or even catecholaminergic neurons. Substantial dopamine production within serotonin and norepinephrine neurons may play a role in either therapeutic effects or adverse effects of therapy with L-DOPA.
Authors:
W D Brown; M D Taylor; A D Roberts; T R Oakes; M J Schueller; J E Holden; L M Malischke; O T DeJesus; R J Nickles
Related Documents :
10150075 - Current and future technological trends in positron emission tomography.
8492135 - In vivo imaging of vesicular monoamine transporters in human brain using [11c]tetrabena...
18460745 - Design considerations for a limited angle, dedicated breast, tof pet scanner.
19834445 - Quantitative small animal pet.
25322115 - Digital holography and 3d imaging: introduction.
20423805 - A novel rotationally invariant region-based hidden markov model for efficient 3-d image...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Neurology     Volume:  53     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1999 Oct 
Date Detail:
Created Date:  1999-12-17     Completed Date:  1999-12-17     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1212-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Radiology, University of Wisconsin-Madison, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Brain / radionuclide imaging*
Dihydroxyphenylalanine / analogs & derivatives*,  diagnostic use
Dopamine / metabolism*
Female
Humans
Kinetics
Levodopa / metabolism*
Male
Middle Aged
Tomography, Emission-Computed
Grant Support
ID/Acronym/Agency:
R29 NS31612/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Levodopa; 63-84-3/Dihydroxyphenylalanine; 75290-51-6/fluorodopa F 18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency.
Next Document:  The tau gene A0 allele and progressive supranuclear palsy.